Table 2.
Correlation between high level of leptin immunoreactivity and clinicopathological parameters in the current study compared to previous studies
| Previous studies | Leptin immunostaining prevalence in breast cancer cases | Leptin immunostaining prevalence in noncancerous breast tissue | Age | Size of tumor | Histotype | Grade | Stage | Recurrence | Lymph Node involvement | Hormone receptor phenotype (ER, PR, HER2) | ER expression | PR expression | HER2 expression | Vascular Invasion | Alive/Deceased status | Survival |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| The current study | 83.7% (61% weak & 22.7% strong) | 92.6% (51.9% weak & 40.7% strong) | P = 0.0233 | NS | P = 0.0001 | All grades low scores P = 0.0500 | P = 0.0291 | P = 0.0023 | P = 0.0300 | ER-, PR+, HER2-P = 0.0021 | ER+ P = 0.0279 | NS | P = 0.0021 | NS | NS | Absent or Weak staining -Poor survival |
| [1] | 100% (7.9% weak & 92.1% strong) | 100% (100% weak) | NS | NS | NS | NS | NS | NS | NS | Overexpression – poor survival | ||||||
| [2] | 60% | 0% | ||||||||||||||
| [3] | 86.4% (30.4% weak & 56% strong) | 43.3% (43.3% weak) | NS | NS | High grade high scores P = 0.031 | NS | NS | |||||||||
| [4] | NS | NS | NS | NS | NS | |||||||||||
| [5] | 79.6% (52.5% weak & 27.1& strong) | 77.5% (50% weak & 27.5% strong) | ||||||||||||||
| [6] | 79.6% | NS | NS | NS | NS | NS | NS | NS | NS | NS | ||||||
| [7] | 85% | 76.5% | NS | NS | NS | |||||||||||
| [8] | 39% | NS | NS | NS | ER-, PR-, HER2-P = 0.022 | NS | NS | NS | NS | |||||||
| [9] | 83% | NS | P < 0.001 | NS | NS | NS | NS | NS | NS | |||||||
| [10] | 61% | 40% | NS | NS | NS |
NS not significant